Michael Reisman

Michael Reisman is an experienced investment banking professional currently serving as an Investment Banking Principal at Centerview Partners since May 2019, specializing in healthcare M&A and strategic advisory. Notable transactions include the $900 million sale of Bolt Medical to Boston Scientific, the $1.4 billion sale of Aliada Therapeutics to AbbVie, and the $4.9 billion sale of Eidos Therapeutics to BridgeBio. Prior to Centerview Partners, Michael gained experience at Lazard as an Investment Banking Analyst focusing on healthcare and completed a summer analyst position at J.P. Morgan with a focus on technology. Michael holds a Bachelor of Arts in Economics from the University of Chicago, graduating in 2018.